Expression, clinicopathologic and prognostic significance of plasminogen activator inhibitor 1 in hepatocellular carcinoma

2020 ◽  
Vol 27 (3) ◽  
pp. 285-293 ◽  
Author(s):  
Ye Jin ◽  
Zhi-Yong Liang ◽  
Wei-Xun Zhou ◽  
Li Zhou
Keyword(s):  
Hepatocellular Carcinoma ◽  
Plasminogen Activator ◽  
Prognostic Significance ◽  
Plasminogen Activator Inhibitor ◽  
Plasminogen Activator Inhibitor 1 ◽  
Activator Inhibitor

Plasminogen Activator Inhibitor 1: A New Prognostic Marker in Septic Shock

1989 ◽  
Vol 61 (03) ◽  
pp. 459-462 ◽  
Author(s):  
Gerard Pralong ◽  
Thierry Calandra ◽  
Michel-P Glausef ◽  
Joop Schellekens ◽  
Jan Verhoef ◽  
...  
Keyword(s):  
Septic Shock ◽  
Plasminogen Activator ◽  
Prognostic Significance ◽  
Elevated Serum ◽  
Plasminogen Activator Inhibitor ◽  
Threshold Level ◽  
Control Group ◽  
Plasminogen Activator Inhibitor 1 ◽  
Activator Inhibitor ◽  
Pai 1

SummaryThe prognostic value of plasminogen activator inhibitor type 1 (PAI-1) in septic shock was investigated in 52 patients with septic shock. The patients had significantly elevated serum PAI-1 levels with respect to the control group (p = 0.002). In patients not having a rapidly fatal underlying disease, PAI-1 was significantly higher in patients dying within a week after onset of shock than in survivors (median PAI-1: 900 and 307 ng/ml, respectively; p = 0.001). The analysis of the distribution of PAI-1 levels permitted retrospectively to determine a threshold level of PAI-1 which had prognostic significance. Mortality was 71% in patients with serum PAI-1 above 550 ng/ml, whereas only two patients (6%) having a PAI-1 below 550 ng/ml died within a week.Thus, in patients with septic shock, PAI-1 appears to have a strong predictive value as to mortality. This early marker may help the clinician in identifying a subgroup of patients particularly at risk.

scholarly journals Plasminogen activator inhibitor (PAI-1) gene polymorphism (4G/5G) and hepatocellular carcinoma in Egyptian patients

2019 ◽  
Vol 43 (1) ◽  
Author(s):  
Nader Nemr ◽  
Mohamed Mandour ◽  
Dahlia Badran ◽  
Rania Kishk ◽  
Fawzy Attia ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Plasminogen Activator ◽  
Plasminogen Activator Inhibitor ◽  
Serum Levels ◽  
Study Groups ◽  
Plasminogen Activator Inhibitor 1 ◽  
Significant Difference ◽  
Chronic Hcv ◽  
Activator Inhibitor ◽  
Pai 1

Abstract Background Plasminogen activator inhibitor-1 (PAI-1), which is a part of urokinase plasminogen activation (uPA) system, had been reported to have a crucial role in the development of different types of cancers. The PAI-1 gene, located on chromosome 7, contains nine exons and eight introns. This gene is highly polymorphic, and its most common polymorphism (4G/5G) affects PAI-1 biosynthesis and consequently its circulating level. Aim The current study investigated the distribution of genotypes and the allelic frequency of the PAI-1 4G/5G polymorphism in hepatocellular carcinoma (HCC) compared to chronic HCV patients living in Egypt. Additionally, the effect of the PAI-1 4G/5G polymorphism on serum PAI-1 levels was assessed. Methods The study was carried on 50 HCC and 47 chronic HCV patients using real-time polymerase chain reaction. Results The genotypic distributions of the 4G/5G polymorphism (5G/5G, 4G/4G, 4G/5G, and 4G/4G + 4G/5G) and the frequency of alleles (5G and 4G) were not statistically significantly different between both study groups (p > 0.05). In addition, serum levels of PAI-1did not show any significant difference between HCC patients and HCV patients regarding all different genotypes of the 5G/4G polymorphism at p > 0.05 neither between the different genotypes of the 5G/4G polymorphism in the same group at p > 0.05. Conclusion Our study suggests that the PAI-1 4G/5G polymorphism may not be considered as one of the underlying genetic causes of hepatocarcinogenesis in chronically HCV-infected patients living in Egypt.

943: Plasminogen Activator Inhibitor 1 (PAI-1) is Increased in Human Peyronie's Disease

2005 ◽  
Vol 173 (4S) ◽  
pp. 255-255 ◽  
Author(s):  
Hugo H. Davila ◽  
Thomas R. Magee ◽  
Freddy Zuniga ◽  
Jacob Rajfer ◽  
Nestor F. GonzalezCadavid
Keyword(s):  
Plasminogen Activator ◽  
Plasminogen Activator Inhibitor ◽  
Peyronie’S Disease ◽  
Plasminogen Activator Inhibitor 1 ◽  
Peyronie's Disease ◽  
Activator Inhibitor ◽  
Pai 1
Sign in / Sign up

Export Citation Format

Share Document